Systematic repurposing screening in xenograft models identifies approved drugs with novel anti-cancer activity.
Ontology highlight
ABSTRACT: Approved drugs target approximately 400 different mechanisms of action, of which as few as 60 are currently used as anti-cancer therapies. Given that on average it takes 10-15 years for a new cancer therapeutic to be approved, and the recent success of drug repurposing for agents such as thalidomide, we hypothesized that effective, safe cancer treatments may be found by testing approved drugs in new therapeutic settings. Here, we report in-vivo testing of a broad compound collection in cancer xenograft models. Using 182 compounds that target 125 unique target mechanisms, we identified 3 drugs that displayed reproducible activity in combination with the chemotherapeutic temozolomide. Candidate drugs appear effective at dose equivalents that exceed current prescription levels, suggesting tha
SUBMITTER: Roix JJ
PROVIDER: S-EPMC4122340 | biostudies-literature | 2014
REPOSITORIES: biostudies-literature
ACCESS DATA